In Brief: SmithKline Beecham's Tagamet HB
This article was originally published in The Tan Sheet
Executive Summary
SmithKline Beecham's Tagamet HB: Single-tablet 200 mg dose is reaching wide distribution. The new form of the OTC H2 antagonist stomach medication was approved Aug. 21 and replaces the former two-per-dose 100 mg tablet. Packaging highlights the "new one-tablet dose" in a yellow flag on the box front. SB reported the approval was earlier this autumn, noting that the dual tablet dosage form had been "a major problem" in consumer perception of Tagamet HB's effectiveness and potency, causing the company to have low market share in the H2 category ("The Tan Sheet" Sept. 16, p. 1)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning